Illumina has named Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, bringing extensive experience in life sciences and diagnostics. Sullivan will lead global commercial operations, leveraging over 30 years in healthcare and precision medicine, while Coletti will oversee legal, regulatory, and governance functions. These leadership additions aim to strengthen Illumina's strategy and growth as it advances genomic and health technologies worldwide.
Illumina, Inc. announced it will report its second quarter 2026 financial results after market close on July 30, 2026. On the same day, CEO Jacob Thaysen and CFO Ankur Dhingra will host a conference call at 1:30 pm Pacific Time to discuss the results...
Illumina dominates the genomics sequencing market with over 90% share, operating in a $30 billion market growing at double-digit rates. The company’s focus on core sequencing, cost control, and capital return after divesting GRAIL is fueling revenue ...
